Coronary calcification and hormones

Angiology

Volumn 62, Issue 7, 2011, Pages 554-564

  Koulaouzidis, George ^a   Henein, Michael ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

adiponectin; coronary calcification; fetuin A; ghrelin; growth hormone; hormones; insulin; insulin resistance; leptin; oestrogen; osteopontin; osteoprotegerin; parathyroid hormone; renin angiotensin; resistin; testosterone; visfatin

Indexed keywords

ANGIOTENSIN; ESTROGEN; GHRELIN; GROWTH HORMONE; HORMONE; LEPTIN; PARATHYROID HORMONE; RENIN; RESISTIN; TESTOSTERONE;

ADIPOSE TISSUE; AGE DISTRIBUTION; ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY CALCIFICATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; ENERGY EXPENDITURE; FOOD INTAKE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; INTERNET; INTRAVASCULAR ULTRASOUND; MEDLINE; NONHUMAN; PERICARDIAL ADIPOSE; POSTMENOPAUSE; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

CORONARY ARTERY DISEASE; FEMALE; GONADAL HORMONES; HUMANS; MALE; PEPTIDE HORMONES; RENIN-ANGIOTENSIN SYSTEM; VASCULAR CALCIFICATION;

EID: 80054717094     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711399418     Document Type: Article

References (120)

1. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest. 1994 ; 94 (4). 1597-604
2. Henein MY, Owen A. Statins moderate coronary stenoses but not coronary calcification: results from meta-analyses. Int J Cardiol. 2010 ;:
3. Doherty TM, Detrano RC, Mautner SL, Maunter GC, Shavelle RM. Coronary calcium: the good, the bad and the uncertain. Am Heart J. 1999 ; 137 (5). 774-776
4. Doherty TM, Detrano RC. Coronary arterial calcification as an active process: a new perspective on an old problem. Calcif Tissue Int. 1994 ; 54 (3). 224-230 (Pubitemid 24076579)
5. Guzman RJ. Clinical, cellular, and molecular aspects of arterial calcification. J Vasc Surg. 2007 ; 45 Suppl A: A57 - A63
6. Watson KE. Pathophysiology of coronary calcification. J Cardiovasc Risk. 2000 ; 7 (2). 93-97 (Pubitemid 30399071)
7. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008 ; 117 (22). 2938-2948 (Pubitemid 351787058)
8. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res. 2006 ; 99 (10). 1044-1059 (Pubitemid 44729928)
9. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995 ; 38 (3). 199-210
10. Mendelsohn ME, Karas RH. The protective effects of oestrogen on the cardiovascular system. N Engl J Med. 1999 ; 340 (23). 1801-1811 (Pubitemid 29266405)
11. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002 ; 53 (3). 605-619 (Pubitemid 34175253)
12. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002 ; 288 (3). 321-333 (Pubitemid 34761611)
13. Hulley S, Furberg C, Barrett-Connor E, et al. No cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up. JAMA. 2002 ; 288 (1). 58-66 (Pubitemid 34705519)
14. McLaughlin VV, Hoff JA, Rich S. Relation between hormone replacement therapy in women and coronary artery disease estimated by electron beam tomography. Am Heart J. 1997 ; 134 (6). 1115-1119 (Pubitemid 28040202)
15. Christian RC, Harrington S, Edwards WD, Oberg AL, Fitzpatrick LA. Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women. J Clin Endocrinol Metab. 2002 ; 87 (3). 1062-1067 (Pubitemid 36121066)
16. Manson JE. Estrogen therapy and coronary artery calcification. N Engl J Med. 2007 ; 356 (25). 2591-2602 (Pubitemid 46961004)
17. Akhrass F, Evans AT, Wang Y, et al. Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J Clin Endocrinol Metab. 2003 ; 88 (12). 5611-5614 (Pubitemid 38033023)
18. Barrett-Connor E, Laughlin GA. Hormone therapy and coronary artery calcification in asymptomatic postmenopausal women: the Rancho Bernardo Study. Menopause. 2005 ; 12 (1). 40-48 (Pubitemid 40204892)
19. Alexandersen P, Tanko LB, Bagger YZ, Qin G, Christiansen C. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric. 2006 ; 9 (2). 108-118
20. Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, Matthews KA. Hormone therapy, lipoprotein subclasses, and coronary calcification. Arch Intern Med. 2005 ; 165 (5). 510-515 (Pubitemid 40344381)
21. Shahar E, Bruke GL, Cushman M, Heckbert SR, Ouyang P, Szklo M. Post menopausal hormones and measures of subclinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis. Prev Med. 2008 ; 47 (1). 38-45
22. Budoff MJ, Chen GP, Hunter CJ, et al. Effects of hormone replacement on progression of coronary calcium as measured by electron beam tomography. J Womens Health. 2005 ; 14 (5). 410-417 (Pubitemid 41052039)
23. Schisterman EF, Gallagher AM, Bairey Merz CN, et al. The association of hormone replacement therapy and coronary calcium as determined by electron beam tomography. J Womens Health Gend Based Med. 2002 ; 11 (7). 631-638
24. Ouyang P, Vaidya D, Dobs A, et al. Sex hormones levels and subclinical atherosclerosis in postmenopausal women: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2009 ; 204 (1). 255-261
25. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010 ; 96 (22). 1821-1825
26. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomised placebo-controlled trials. Mayo Clin Proc. 2007 ; 82 (1). 29-39 (Pubitemid 46036319)
27. McRobb L, Handelsman DJ, Heather AK. Androgen-induced progression of arterial calcification in apolipoprotein E-null mice is uncoupled from plaque growth and lipid levels. Endocrinology. 2009 ; 150 (2). 841-848
28. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000 ; 343 (25). 1863-1875 (Pubitemid 32104134)
29. Yu N, Donnan PT, Flynn RWV, et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. Clinical Endocrinology. 2010 ; 73 (1). 30-34
30. Arad Y, Spadaro LA, Roth M, et al. Serum concentration of calcium, 1,25 vitamin D and parathyroid hormone are not correlated with coronary calcifications. An electron beam tomography study. Coron Artery Dis. 1998 ; 9 (8). 513-518 (Pubitemid 28517595)
31. Streeten EA, Munir K, Hines S, et al. Coronary artery calcification in patients with primary hyperparathyroidism in comparison with control subjects from the multi-ethnic study of atherosclerosis. Endocr Pract. 2008 ; 14 (2). 155-161
32. Kepez A, Harmanci A, Hazirolan T, et al. Evaluation of subclinical coronary atherosclerosis in mild asymptomatic primary hyperparathyroidism patients. Int J Cardiovasc Imaging. 2009 ; 25 (2). 187-193
33. Hernandes FR, Barreto FC, Rocha LA, Drabe SA, Canziani ME, Carvalho AB. Evaluation of the role of severe hyperparathyroidism on coronary artery calcification in dialysis patients. Clin Nephrol. 2007 ; 67 (2). 89-95 (Pubitemid 46322560)
34. Bogazzi F, Battolla L, Spinelli C, et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab. 2007 ; 92 (11). 4271-4277 (Pubitemid 350080942)
35. Herrmann BL, Severing M, Schmermund A, et al. Impact of disease duration on coronary calcification in patients with acromegaly. Exp Clin endocrinol Diab. 2009 ; 117 (8). 417-422
36. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999 ; 402 (6762). 656-660 (Pubitemid 129516334)
37. Li GZ, Jiang W, Zhao J, et al. Ghrelin blunted vascular calcification in vivo and in vitro rats. Regul Pept. 2005 ; 129 (1-3). 167-76 (Pubitemid 40775800)
38. Pfohl M, Athanasiadis A, Koch M, et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound. J Am Coll Cardiol. 1998 ; 31 (5). 987-991 (Pubitemid 28212497)
39. Mattu RK, Needham EW, Galton DJ, Frangos E, Clark AJ, Caulfied M. A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study. Circulation. 1995 ; 91 (2). 270-274
40. Nsengimana J, Barrett JH. Renin-angiotensin system genes and coronary artery calcification. Future Cardiol. 2007 ; 3 (6). 587-590
41. Oei HH, Sayed-Tabatabaei FA, Hofman A, Oudkerk M, Van Duijin CM, Witteman JC. The association between angiotensin-converting enzyme gene polymorphism and coronary calcification. The Rotterdam Coronary Calcification Study. Atherosclerosis. 2005 ; 182 (1). 169-73 (Pubitemid 41188383)
42. Pischon T, Rimm E. Adiponectin: a promising marker for cardiovascular disease. Clin Chem. 2006 ; 52 (5). 797-799 (Pubitemid 43673256)
43. Oh DK, Giaraldi T, Henry RR. Adiponectin in health and disease. Diabetes Obes Metab. 2007 ; 9 (3). 282-289 (Pubitemid 46502045)
44. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol. 2003 ; 14 (6). 561-566 (Pubitemid 41623184)
45. Behre CJ. Adiponectin, obesity and atherosclerosis. Scand J Clin Lab Invest. 2007 ; 67 (5). 449-458 (Pubitemid 47353945)
46. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipatrophy and obesity. Nat Med. 2001 ; 7 (8). 941-946 (Pubitemid 32756432)
47. Lawlor DA, Davey Smith G, Ebrahim S, Thompson C, Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab. 2005 ; 90 (10). 5677-5683 (Pubitemid 41415475)
48. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 2005 ; 54 (2). 534-539
49. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004 ; 291 (14). 1730-1737 (Pubitemid 38489895)
50. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary disease in men. Arterioscler Thromb Vasc Biol. 2003 ; 23 (1). 85-89 (Pubitemid 36091630)
51. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002 ; 106 (22). 2767-2770 (Pubitemid 35396973)
52. Marso SP, Mehta SK, Frutkin A, House JA, McCrary JR, Kulkarni KR. Low adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich plaque in nondiabetic coronary arteries. Diabetes Care. 2008 ; 31 (5). 989-994
53. Greif M, Becker A, von Ziegler F, et al. Pericardial adipose tissue determined by dual source CT is a risk factor for coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2009 ; 29 (5). 781-786
54. Maahs DM, Ogden LG, Kinney GL, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005 ; 111 (6). 747-753 (Pubitemid 40250635)
55. Qasim A, Mehta NN, Tadesse MG, et al. Adipokines, insulin resistance and coronary artery calcification. J Am Coll Cardiol. 2008 ; 52 (3). 231-236 (Pubitemid 351915780)
56. Broedl UC, Lebherz C, Lehrke M, et al. Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques. PLoS One. 2009 ; 4 (3). e4733
57. Chung CP, Long AG, Solus JF, et al. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus. 2009 ; 18 (9). 799-806
58. Rho YH, Chung CP, Solus JF, et al. Adipocytokines, insulin, and coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2010 ; 62 (5). 1259-1264
59. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006 ; 189 (1). 47-60 (Pubitemid 44441296)
60. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001 ; 104 (25). 3052-3056 (Pubitemid 34014056)
61. Poulakou MV, Paraskevas KI, Wilson MR, et al. Apolipoprotein J and leptin levels in patients with coronary heart disease. In Vivo. 2008 ; 22 (4). 537-542
62. Iribarren C, Husson G, Go AS, et al. Plasma leptin levels and coronary artery calcification in older adults. J Clin Endocrinol Metab. 2007 ; 92 (2). 729-732
63. Reilly MP, Iqbal N, Schutta M, et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab. 2004 ; 89 (8). 3872-3878 (Pubitemid 39071487)
64. Wolk R, Begger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004 ; 44 (9). 1819-1824 (Pubitemid 39424081)
65. Zeadin M, Butcher M, Werstuck G, Khan M, Yee CK, Shaughnessy SG. Effect of leptin on vascular calcification in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2009 ; 29 (12). 2069-2075
66. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005 ; 111 (7). 932-939 (Pubitemid 40279897)
67. Weikert C, Westphal S, Berger K, et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab. 2008 ; 93 (7). 2647-2653 (Pubitemid 352008532)
68. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP. VISFATIN/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol. 2010 ;:
69. Saddi-Rosa P, Oliveira CS, Giuffrida F, Reis AF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr. 2010 ; 2: 21
70. Uz Ö, Karde?oD lu E, Yiginer Ö, et al. The relationship between coronary calcification and metabolic markers of osteopontin, fetuin-A and visfatin. Turk Kardiyol Dern Ars. 2009 ; 37 (6). 397-402
71. Van Campenhourt A, Golledge J. Osteoprotegerin. Vascular calcification and atherosclerosis. Atherosclerosis. 2009 ; 204 (2). 321-329
72. Simonet WS, Lacey DL, Dustan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 ; 89 (2). 309-19 (Pubitemid 27199902)
73. Hofbauer LC, Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum. 2001 ; 44 (2). 253-259 (Pubitemid 32207017)
74. Ashley DT, O' Sullivan EP, Davenport C, et al. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. Metabolism. 2010 ;:
75. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004 ; 109 (18). 2175-2180 (Pubitemid 38625393)
76. Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol. 2010 ; 55 (19). 2049-2061
77. Avignon A, Sultan A, Piot C, et al. Osteoprotegerin: a novel of independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007 ; 30 (11). 2934-2939 (Pubitemid 350083147)
78. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004 ; 44 (10). 1970-1976 (Pubitemid 39473280)
79. Omland T, Ueland T, Jansson AM, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008 ; 51 (6). 627-633 (Pubitemid 351193104)
80. Browner WS, Lui LY, Cummings SR. Associations of serum ostreoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001 ; 86 (2). 631-637 (Pubitemid 32207471)
81. Morony S, Tintut Y, Cattlet RC, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr (?/?) Mice. Circulation. 2008 ; 117 (3). 411-420
82. Mesquita M, Demulder A, Damry N, et al. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin Chem Lab Med. 2009 ; 47 (3). 339-346
83. Kurnatowska I, Grzelak P, Kaczmarska M, Stefa?czyk L, Nowicki M. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. Nephron Clin Pract. 2010 ; 117 (4). c297 - c304
84. Mikami S, Hamano T, Fujii N, et al. Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients. Hypertens Res. 2008 ; 31 (6). 1163-1170
85. Barreto DV, Barreto FC, Carvalho AB, et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int. 2005 ; 67 (4). 1576-1582
86. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006 ; 47 (9). 1850-1857
87. Kwon HM, Hong BK, Kang TS, et al. Expression of osteopontin in calcified coronary atherosclerotic plaques. J Korean Med Sci. 2000 ; 15 (5). 485-493
88. O'Brien ER, Garvin MR, Stewart DK, et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb. 1994 ; 14 (10). 1648-1656
89. Boskey Al, Maresca M, Ullrich W, Doty SB, Butler WT, Prince CW. Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner. 1993 ; 22 (2). 147-159 (Pubitemid 23272798)
90. Wada T, McKee MD, Steitz S, Giachelli CM. Calcification of vascular smmoth cell cultures: inhibition by osteopontin. Circ Res. 1999 ; 84 (2). 166-178 (Pubitemid 29070112)
91. Li G, Chen YF, Kelpke SS, Oparil S, Thompson JA. Estrogen attenuates integrin-beta?(3)-dependent adventitial fibroblast migration after inhibition of osteopontin production in vascular smooth muscle cells. Circulation. 2000 ; 101 (25). 2949-55 (Pubitemid 30415886)
92. Aryan M, Kepez A, Atalar E, et al. Association of plasma osteopontin levels with coronary calcification evaluated by tomographic coronary calcium scoring. J Bone Miner Metab. 2009 ; 27 (5). 591-597
93. Ohmori R, Momiyama Y, Taniguchi H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis. 2003 ; 170 (2). 333-337 (Pubitemid 37377807)
94. Schurgin S, Rich S, Mazzone T. Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care. 2001 ; 24 (2). 335-338 (Pubitemid 32119134)
95. Dabelea S, Kinney G, Snell-Bergeon JK, et al. Effect of type 1diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes. 2003 ; 52 (11). 2833-2839 (Pubitemid 37339714)
96. Tanaka M, Fukui M, Tomiyasu K, et al. U-shaped relationship between insulin level and coronary artery calcification (CAC). J Atheroscler Thromb. 2010 ; 17 (10). 1033-1040
97. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988 ; 37 (12). 1595-1607 (Pubitemid 19004941)
98. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care. 2007 ; 30 (3). 707-712 (Pubitemid 46354357)
99. Arad Y, Newstein D, Cadet F, Roth M, Guerci AD. Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study. Arterioscler Thromb Vasc Biol. 2001 ; 21 (12). 2051-2058 (Pubitemid 34219761)
100. Rodrigues TC, Biavatti K, Almeida FK, Gross JL. Coronary artery calcification is associated with insulin resistance index in patients with type 1 diabetes. Braz J Med Biol Res. 2010 ; 43 (11). 1084-1087
101. Elkeles RS, Godsland IF, Feher MD, et al. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J. 2008 ; 29 (18). 2244-2251
102. Maurovich-Horvat P, Móri T, Kerecsen G, et al. Assessment of coronary artery calcification using dual-source computed tomography in adult asymptomatic patients with type 1 diabetes mellitus. Med Sci Monit. 2010 ; 16 (7). MT59 - MT64
103. Lee KK, Fortmann SP, Fair JM, et al. Insulin resistance independently predicts the progression of coronary artery calcification. Am Heart J. 2009 ; 157 (5). 939-945
104. Kobayashi S, Oka M, Maesato K, et al. Coronary artery calcification, ADMA, and insulin resistance in CKD patients. Clin J Am Soc Nephrol. 2008 ; 3 (5). 1289-1295
105. Schauer IE, Snell-Bergeon JK, Bergman BC, et al. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes. 2010 ;:
106. Rennenberg RJ, Schurgers LJ, Kroon AA, Stehouwer CD. Arterial calcifications. J Cell Mol Med J. 2010 ; 14 (9). 2203-2210
107. Kirkpantur A, Altun B, Hazirolan T, et al. Association among serum fetuin-A level, coronary artery calcification, and bone mineral densitometry in maintenance hemodialysis patients. Artif Organs. 2009 ; 33 (10). 844-854
108. Lorant DP, Grujicic M, Hoebaus C, et al. Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care. 2010 ;:
109. Suliman ME, García-López E, Anderstam B, Lindholm B, Stenvinkel P. Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease. Adv Clin Chem. 2008 ; 46: 217-262
110. Westenfeld R, Schäfer C, Krüger T, et al. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol. 2009 ; 20 (6). 1264-1274
111. Zhang B, Shi W, He CS, Liang XL, Liu SX, Liang YZ. [Low serum fetuin A is a risk factor of coronary artery calcification in patients starting hemodialysis]. [Article in Chinese] Nan Fang Yi Ke Da Xue Xue Bao. 2010 ; 30 (3). 1002-4
112. Mori K, Ikari Y, Jono S, et al. Fetuin-A is associated with calcified coronary artery disease. Coron Artery Dis. 2010 ; 21 (5). 281-285
113. Mehrotra R, Westenfeld R, Christenson P, et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 2005 ; 67 (3). 1070-1077 (Pubitemid 41623332)
114. Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant. 2006 ; 21 (7). 1915-1920 (Pubitemid 43985720)
115. Greenland P, Labree L, Azen SP, Doherty TM, Detrano RC. Coronary calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004 ; 291 (2). 210-215 (Pubitemid 38082815)
116. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology. 2003 ; 228 (3). 826-833 (Pubitemid 37025495)
117. Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003 ; 107 (20). 2571-2576 (Pubitemid 36628938)
118. Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999 ; 74 (3). 243-252 (Pubitemid 29135631)
119. Budoff MJ, Raggi P. Coronary artery disease progression assessed by electron beam computed tomography. Am J Cardiol. 2001 ; 88 (2A). 46E - 50E (Pubitemid 32721986)
120. Karsenty G. The complexities of skeletal biology. Nature. 2003 ; 423 (6937). 316-318 (Pubitemid 40852704)